BA3182 in Patients with Advanced Adenocarcinoma

I'm Interested!

Please call
1-800-641-2422

An Open-label, Multicenter, Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, a Bispecific Epithelial Cell Adhesion Molecule (EpCAM)/CD3 Antibody, in Patients with Advanced Adenocarcinoma

Sex at Birth: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Solid Tumor

Study Purpose

The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma

Principal Investigator
Jennifer Selfridge MD PhD

Department/Division
Cancer (Any Solid Tumor)

Locations

UH Seidman Cancer Center
11100 Euclid Avenue
Cleveland OH, 44106

Get Directions

UH IRB: STUDY20230177
StudyID: BATLA1Y23
ClinicalTrials.gov: NCT05808634

I'm Interested!

Please call
1-800-641-2422

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422